High Borrow Costs for SLS
SELLAS Life Sciences Group (SLS) has been identified as having one of the highest borrow fees in the current market for stocks with a short value exceeding $1 million. This elevated cost to borrow is a clear indicator that shares are difficult to source, reflecting high demand from short sellers and limited supply from lenders.
Implications for Traders
For those looking to short SLS, the high borrow fee acts as a significant headwind, increasing the cost of maintaining a position over time. Conversely, for existing short sellers, the high fee may indicate a crowded trade or a potential squeeze setup if the stock price begins to rise. Traders should exercise caution and monitor the borrow fee daily, as rapid changes in availability can lead to sudden spikes in the cost to borrow.
Signal data sourced from Interactive Brokers. This post is an original analysis prepared by The Forensic Ledger from publicly available data. Not investment advice.
Not investment advice. This is original reporting and analysis prepared by The Forensic Ledger from publicly available data. Nothing here is a recommendation to buy, sell, or hold any security. Always consult the original source and a licensed professional. See our full disclaimer and source-citation policy.